Angiogenesis inhibitors in oncology: The research continues

Cancer Practice

Volumn 8, Issue 3, 2000, Pages 148-150

  Philip, Sephy ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; TANOMASTAT; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; ENDOTHELIUM CELL; ENZYME INHIBITION; GROWTH INHIBITION; GYNECOLOGIC CANCER; HEAD AND NECK TUMOR; HEMANGIOMA; HUMAN; KAPOSI SARCOMA; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; UROGENITAL TRACT CANCER;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENDOTHELIAL GROWTH FACTORS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; TREATMENT OUTCOME;

EID: 0034015520     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.2000.83010.x     Document Type: Review

References (12)

1. Folkman J, Long DM, Decker FF. Tumor growth in organ culture. Surg Forum. 1962;13:164-166.
2. National Cancer Institute. Anti-Anglogenesis Information. Bethesda, Md:National Cancer Institute; 1999. Available at:http://cancertrials.nci.nih.gov/NCI_CANCER_TRIALS/zones/ PressInfo/Angio/index.html. Accessed November 25, 1999.
3. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 1999;58:17-38.
4. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
5. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal antivascular endothelial growth factor (antiVEGF MAB) in patients (pts) with metastatic cancer. Proc Am Soc Clin Oncol Annu Meet. 1998;17:210.
6. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (F1K - 1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
7. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997;3:1501-1505.
8. Gervaz P, Fontolliet C. Therapeutic potential of the antiangiogenesis drug TNP-470. Int J Exp Pathol. 1998;79:359-362.
9. Valorie AM. Thalidomide:a new beginning. Cancer Pract. 2000;8:101-103.
10. O'Reilly M, Boehm T, Shing Y, et al. Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88:277-285.
11. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997:390:404-407.
12. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999:107:174-180.